VEGF Trap-Eye Phase 2 trial reports significant improvement in neovascular disease
Regeneron Pharmaceuticals, Inc and Bayer HealthCare AG has announced the result of Phase 2 trial of the VEGF Trap-Eye. It reported to have achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size.